Program

HIGHWAY to Tech, Money and Skills

Press Briefing: The drug Myrcludex B is included in the European scheme PRIME

6 June 11:45-12:15 // Location: Press Center

Press Briefing: The drug Myrcludex B is included in the European scheme PRIME
Speakers Dmitry Popov, Chairman of the Board of Directors of LLC "Gepatera", Managing Partner of Maxwell Biotech Group; Alexander Alexandrov, Development Director of LLC "Gepatera"; Kirill Kayem , Vice President, Executive Director of the Cluster of Biological and Medical Technologies of the Skolkovo Foundation. Moderator: Kamila Zarubina, Senior Project Manager, Cluster BMT, Foundation "Skolkovo"

Topic: Resident of the Cluster Biomedical Technologies of the Skolkovo Foundation, Hepatera, and its partner MYR GmbH, announced that the European Medicines Agency (EMA) has approved the eligibility of the drug Myrcudex B in its PRIME scheme, intended for the treatment of hepatitis B with Delta agent. This is the first Russian development and the first anti-infective drug included in the PRIME scheme.

Speakers

Dmitry Popov

Hepatera

Kirill Kaem

Skolkovo Foundation

Alexander Alexandrov

Hepatera

Moderators

Kamila Zarubina

Skolkovo Foundation